- In October 2023, Koninklijke Philips N.V., a global leader in health technology, announced a two-year partnership with the World Stroke Organization (WSO), the only global non-governmental organization dedicated to stroke. This collaboration aims to enhance access to high-quality stroke care around the world, addressing critical gaps in treatment and support. By leveraging Philips' technological expertise and WSO's advocacy, the partnership seeks to improve outcomes for stroke patients and promote better healthcare practices on a global scale
- In July 2022, Siemens Healthineers received FDA clearance for the MAGNETOM Free.Star, an affordable whole-body magnetic resonance (MR) scanner aimed at enhancing patient access to MRI technology. This innovative device is designed to provide high-quality imaging while reducing costs, making MRI more accessible to healthcare facilities and patients alike. By addressing the barriers related to MRI availability, the MAGNETOM Free.Star is poised to play a crucial role in improving diagnostic capabilities in various clinical settings
- In July 2021, Siemens Healthineers announced that the FDA granted clearance for the MAGNETOM Free.Max, an advanced high-V magnetic resonance (MR) scanner. This innovative device features a 0.55 Tesla (0.55T) field strength and integrates deep learning technologies along with sophisticated image processing capabilities. The combination of these cutting-edge features enhances imaging quality and efficiency, positioning the MAGNETOM Free.Max as a valuable tool for improving diagnostic accuracy in various medical settings
- In August 2021, Abbott announced that the U.S. Food and Drug Administration (FDA) had approved its Amplatzer Amulet Left Atrial Appendage Occluder for use in patients with atrial fibrillation (AFib) who are at risk of ischemic stroke. This innovative device is designed to effectively reduce the risk of stroke by occluding the left atrial appendage, where blood clots often form in AFib patients. With this approval, Abbott aims to enhance patient safety and outcomes for individuals vulnerable to stroke associated with AFib
- In November 2020, AstraZeneca announced that it had received approval for Brilinta (ticagrelor) in the United States to lower the risk of stroke, a major contributor to disability and mortality worldwide. This approval specifically targets patients experiencing acute ischemic stroke (with a National Institutes of Health Stroke Scale score of ≤5) or those at high risk of transient ischemic attack. By offering this innovative treatment option, AstraZeneca aims to enhance patient outcomes and address the urgent need for effective stroke prevention strategies
